학술논문
690 High safety and efficacy of CRISPR-Based non-viral PD1 locus specific Integrated Anti-CD19 CAR-T cells (BRL-201) in treating relapsed or refractory non-Hodgkin’s lymphoma: first-in-human phase I study
Document Type
article
Author
Source
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Subject
Language
English
ISSN
2051-1426